SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp (BULL) is trending as investors debate its breakout potential, with the community closely tracking its recent push above key moving averages and positive analyst price target revisions. While some traders are aggressively buying the dip in anticipation of institutional short covering and a potential squeeze toward double digits, others remain skeptical due to historical volatility and the stock's tendency to trade in a tight range compared to sector peers like Robinhood.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant market volatility and high trading volume following the FDA's acceptance of sNDA submissions for its Duchenne muscular dystrophy therapies, with a target action date set for early 2027. The community is actively debating whether this news serves as a de-risking catalyst or if the stock remains trapped in a long-term range, with many investors pointing to suppressed valuations and institutional accumulation as signs of a potential future buyout or short squeeze.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as it experiences significant price volatility, with investors closely watching institutional support levels and debating the long-term impact of hyperscaler capacity announcements on the broader AI infrastructure sector. Community sentiment remains polarized, with some traders viewing the recent pullback as a tactical entry opportunity based on upcoming contract catalysts and pipeline execution, while others express concern over sector-wide sentiment shifts and algorithmic trading activity.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending following the completion of its Phase 3 APPROACH study enrollment ahead of schedule, a significant clinical milestone that keeps the company on track for its topline data readout in late 2026. The community is actively discussing the company's progress with its lead asset, HLP003, while weighing the potential impact of industry-wide regulatory developments and the firm's ongoing capital requirements.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen Inc. (PGEN) is experiencing heightened investor interest driven by a successful commercial launch of its RRP treatment and anticipation surrounding Q1 earnings, with the community actively discussing potential institutional accumulation and the stock's positioning against short interest. Discussions center on the company's progress toward cash-flow breakeven, the impact of a permanent J-code on revenue acceleration, and optimistic speculation regarding future pipeline developments like PRGN-2009.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending as investors react to a significant partnership with Apple to power its new device leasing program, fueling intense debate over the stock's growth potential versus short-term volatility. While bulls cite this collaboration and broader fintech expansion as long-term catalysts, others are closely watching for technical breakouts and remain skeptical about the sustainability of recent price action.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility driven by significant geopolitical tensions in the Middle East, tariff-related uncertainty, and conflicting institutional perspectives on the sustainability of the ongoing AI and semiconductor sector rally. Market participants are actively debating whether the persistent strength in tech is a genuine indicator of growth or an artificial liquidity-driven move vulnerable to a sudden correction.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is trending as traders grapple with a rally that persists despite rising energy costs, ongoing geopolitical tensions in the Middle East, and significant tariff concerns. Community discussions are dominated by confusion over the market's apparent decoupling from fundamental headwinds, leading to intense debates between those betting on an imminent pullback and those continuing to buy the dip.

Honeywell Aerospace, Inc. manufactures aircraft engines, avionics, and satellite systems. The private company is located in the US.

Honeywell Aerospace Inc

Honeywell Aerospace

Honeywell Aerospace is trending due to persistent selling pressure following its recent spinoff, with investors debating whether the price decline represents an attractive buying opportunity or a reflection of underlying supply chain and debt concerns. Community discourse is heavily focused on comparing the stocks current volatility to historical post-spinoff patterns while highlighting positive catalysts like major equipment contracts and upcoming earnings.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing significant retail interest and massive trading volume as investors focus on its expansion into autonomous defense, highlighted by a new counter-drone contract with the Australian Department of Defence. Community discourse remains highly polarized, featuring vocal debates between long-term investors tracking fundamental growth catalysts and skeptics focused on technical volatility and short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026...

Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.

Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down

ZTS misses on Q1 earnings and cuts its 2026 revenue outlook as weaker U.S. companion animal sales pressured results, sending shares down in pre-market trading.

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in the development of antibody product candidates. The firm’s product pipeline includes ANB030, ANB030, and Imsidolimab. It also offers the SHM platform that replicates the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal

Equity

Bullish Sentiment

Too early to tell

Neocloud stocks, including $NBIS and $CRWV, have been under significant selling pressure in recent weeks. Is the selloff finally over? Cast your vote and drop your reasoning in the comments.

Is the pullback in neocloud stocks over?  
 
Explain your reasoning in the comments.

Current Price	$51.30
Prev Close	$50.29
Open	$49.89
Dividend Yield	0.00%
50-Day Moving Average	$59.62
Beta	0.83
Avg. Volume	599,537.72
PE Ratio	-46.55

52-Week High	$72.36
52-Week Low	$11.40
Market Capitalization	$1.49B
EPS (Annual)	-$0.4601
Price to Book	114.53
Revenue Per Employee	$2.26M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANABAnaptysBio Inc

Latest ANAB News